Elevance Health posted third-quarter operating revenue of $50.4 billion, reported results ahead of expectations, and raised its full-year guidance for the third consecutive quarter. The headline numbers were solid. But buried in the membership table is a trend that says more about where the employer health market is heading than any earnings-per-share figure: the company’s fully insured employer group risk book fell 6.9% year over year, while its employer group fee-based membership grew.
Employer group risk-based enrollment stood at 3.366 million as of September 30, down from 3.616 million a year earlier. That 250,000-member decline follows attrition of a similar scale through Q1 and Q2, and lands as the group risk book approaches the high single-digit percentage decline Kaye projected at the start of the year. At the same time, Elevance’s employer group fee-based membership, the self-funded book it administers for employers who carry their own claims risk, grew 1.9% to 21 million.
Chief financial officer Mark Kaye told analysts as far back as the Q4 2025 earnings call that the company expected its employer group risk membership to end 2026 down in the high single-digit percentage range, driven by deliberate pricing decisions on lower-margin public-sector business.
The operating margin in Elevance’s health benefits segment came in at 1% in Q3 2026, down from 1.4% a year earlier. That contraction reflects both the drag of lower risk-based membership and the targeted investments Elevance said it is making to support its long-term operating model. Premium revenue on the commercial side did grow, driven by higher yields across all lines, but higher yields on a shrinking risk book only go so far.
The company’s benefit expense ratio improved 70 basis points year over year to 90.6%, helped by better performance in Medicare Advantage and individual ACA. But operating expense as a percentage of revenue rose 90 basis points to 11.4%, partly reflecting those one-time investments. The net result was a sharp year-over-year decline in Health Benefits operating gain, reflecting the combined pressure of lower risk-based membership and higher operating costs.
While the insurance side compressed, Carelon, Elevance’s services and pharmacy arm, expanded. CarelonRx’s operating gain rose 10.8% year over year and Carelon Services grew 33.3%, with Carelon’s overall margin widening from 4.2% to 4.7%. CarelonRx’s operating gain rose 10.8%, while Carelon Services grew 33.3%. Carelon is carrying an increasing share of the company’s operating gain as health benefits margins narrow. CEO Gail Boudreaux said the company remains confident in returning to at least 12% adjusted diluted EPS growth in 2027 off a higher earnings baseline.
Elevance’s numbers reflect a market-level shift that has accelerated throughout 2026. Industry-wide data tracking employer health coverage enrollment trends and the self-funding shift shows fully insured employer-group risk plans shed approximately two million members as self-funded arrangements grew.
Administrative services only (ASO) plans now account for 43.5% of total US health enrollment, the largest single segment in the country, according to Mark Farrah Associates’ mid-2026 enrollment analysis. The same dynamic showed up in UnitedHealth Group’s Q3 results, where risk-based commercial enrollment fell from 8.165 million at year-end 2025 to 7.575 million by September 30, a drop of 590,000 over nine months.
Each employer that migrates from a fully insured plan to a self-funded arrangement changes the nature of the advisory relationship. The carrier absorbs less risk; the employer absorbs more; and the conversation shifts toward plan design, stop-loss procurement, and claims management in ways a traditional fully insured renewal does not require. Elevance’s fee-based membership growth, the fastest-growing segment in its commercial book, measures exactly that migration in progress.
Those membership and margin dynamics sit against a broader financial picture that remained ahead of expectations. The company’s full-year adjusted diluted EPS guidance now stands at least $29.00, raised from at least $27.00 following Q2. Operating cash flow guidance was lifted to at least $6.5 billion. On a GAAP basis, year-to-date results continue to carry the impact of a $935 million accrual booked in Q1 related to a Centers for Medicare and Medicaid Services (CMS) notice concerning historical Medicare Advantage risk adjustment data.
